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Abstract
Background:  Ets transcription factors have been widely implicated in the control of
tumorigenesis, with most studies suggesting tumor-promoting roles. However, few studies have
examined Ets tumorigenesis-modifying functions in vivo using model genetic systems.
Methods: Using mice expressing a previously characterized Ets dominant repressor transgene in
the intestinal epithelium (Villin-En/Erm), we examined the consequences of blocking endogenous
Ets-mediated transcriptional activation on tumorigenesis in the ApcMin  model of intestinal
carcinoma.
Results:  En/Erm expression in the intestine, at levels not associated with overt crypt-villus
dysmorphogenesis, results in a marked increase in tumor number in ApcMin animals. Moreover,
when examined histologically, tumors from En/Erm-expressing animals show a trend toward
greater stromal invasiveness. Detailed analysis of crypt-villus homeostasis in these En/Erm
transgenic animals suggests increased epithelial turnover as one possible mechanism for the
enhanced tumorigenesis.
Conclusion: Our findings provide in vivo evidence for a tumor-restricting function of endogenous
Ets factors in the intestinal epithelium.
Background
Members of the Ets transcription family, numbering up to
27 in humans, are widely expressed in developing and
mature tissues, and regulate diverse cellular processes
[1,2]. Ets factors are also frequently misexpressed in the
setting of neoplasia. Many Ets factors become overex-
pressed in tumors and appear to play tumor-promoting
roles, while a limited number, notably the epithelial spe-
cific Ets, may perform tumor suppressor functions [1,3-5].
However, to date, most information about Ets functions
in tumorigenesis has come from cell culture and animal
xenograft models. Indeed, very few studies have examined
Ets functions in tumorigenesis in vivo using model genetic
systems [6-8]. Ets factors are widely expressed in the intes-
tine, and often misexpressed in carcinoma of the colon,
but their tumor-modifying roles in intestinal epithelial
neoplasia in vivo largely remain to be defined [9].
We have previously generated and characterized trans-
genic mice expressing an Ets dominant repressor (En/
Published: 22 June 2009
BMC Cancer 2009, 9:197 doi:10.1186/1471-2407-9-197
Received: 23 December 2008
Accepted: 22 June 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/197
© 2009 Jedlicka et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:197 http://www.biomedcentral.com/1471-2407/9/197
Page 2 of 8
(page number not for citation purposes)
Erm) with broad Ets-blocking activity in the small intesti-
nal epithelium [10]. Nearly all members of the Ets tran-
scription factor family are expressed in the mature
mammalian intestine, but expression levels vary widely
[9,11]. Our previous study characterized the phenotypic
consequences of transgene expression at immunohisto-
chemically detectable levels, which resulted in marked
disturbance of crypt-villus homeostasis [10]. Additional
transgenic lines, expressing En/Erm at levels detectable by
RT-PCR but not immunohistochemistry ("low
expressors"), did not manifest an overt dysmorphogenic
phenotype under normal physiologic conditions, despite
the fact that En/Erm is able to block Ets activity at substo-
ichiometric levels in vitro [10]. To determine whether this
low-level En/Erm expression has phenotypic conse-
quences under pathologic conditions, we tested its effect
on intestinal epithelial tumorigenesis in the ApcMin
mouse, a well-established model of multiple intestinal
neoplasia [12-14].
We find that animals with low-level En/Erm expression
develop more than twice as many tumors in the small
intestine as non-transgenic ApcMin controls. Interestingly,
while these animals do not manifest the overt crypt-villus
dysmorphogenesis phenotype under conditions of home-
ostasis previously described for high-level En/Erm
expressors [10], they do show a mild increase in epithelial
transit. Thus, the increase in tumor number in the En/Erm
animals may in part be due to increased crypt-villus epi-
thelial turnover. Moreover, on histologic analysis, tumors
from En/Erm-expressing animals show a trend toward
greater stromal invasion. Our studies in a genetic tumor
model thus uncover an unexpected role for epithelially
expressed Ets factors in the restriction of tumorigenesis in
the intestine.
Methods
Animals
Villin-En/Erm transgenic animals were generated as previ-
ously described [10], and were maintained in an FVB/N
background. ApcMin/+ animals were obtained from Jack-
son Laboratories and were maintained in a C57BL/6J
genetic background. Experimental and control animals
for the tumor study were both derived from a cross
between Villin-En/Erm animals and ApcMin/+ animals. The
studies were thus carried out in a hybrid (C57BL/6J × FVB/
N) background, as done by others [15]. In order to control
for possible confounding effects of the modifier-of-Min
locus (Mom1), the major modifier of tumor multiplicity
in the ApcMin strain [16], the Mom1 genotype (resistant
versus sensitive) was determined, as previously described
[15,17], and such analyses indicated that all animals in
the study were heterozygous (Mom1S/R) for the Mom1
locus. The presence of the Villin-En/Erm transgene and
ApcMin mutation were determined by PCR genotyping of
tail-biopsy DNA, as previously described ([10]; http://
jaxmice.jax.org). Tumor number, size and histology in
ApcMin and ApcMin;Villin-En/Erm animals were evaluated
in H+E-stained sections of the complete length of the
small intestine by a pathologist (PJ) blinded to the geno-
type. All animal work was carried out under protocols
approved by the Institutional Animal Care and Use Com-
mittee.
Histology and immunohistochemistry
Animals were euthanized using CO2 followed by cervical
dislocation. The small intestine was immediately har-
vested and cut into two to three segments of approxi-
mately equal length. Fecal contents were gently expelled,
the lumen was injected with fixative (4% paraformalde-
hyde), and the intestine was rolled concentrically and
placed in a histology cassette. Fixation was for 24 hours in
4% paraformaldehyde at 4°C, after which the tissues were
placed in 70% ethanol, processed further on a standard
histology processor and paraffin-embedded. Sections 4
um thick were stained with hematoxylin and eosin (H+E)
or processed further for immunohistochemical staining.
For immunohistochemical staining, sections were depar-
affinized and rehydrated. Antigen retrieval was performed
by incubating the slides in 10 mM sodium citrate buffer,
pH 6.0, for 1 hour in a Biocare Medical Decloaker. Endog-
enous peroxidase activity was blocked by incubation in
3% H2O2 for 10 minutes. Immunohistochemical staining
was performed using the M.O.M. (mouse on mouse) kit
(Vector Laboratories), and developed using DAB (Dako or
Sigma). Primary antibodies used were mouse anti-smooth
muscle actin (Dako, 1:100) and mouse anti-E-cadherin
(BD Biosciences, 1:100). Mcm6 and b-catenin immuno-
histochemical staining, and BrdU labeling and immuno-
histochemical staining were performed as described
previously [10]. All immunohistochemically stained
slides were counterstained with hematoxylin, dehydrated,
mounted and coverslipped.
RT-PCR
Following euthanasia, the small intestine was removed,
cut into multiple segments and fecal contents were gently
expelled. The intestinal segments were opened lengthwise
and stored in RNAlater (Ambion) at 4°C overnight. The
tissue was removed from RNAlater and laid mucosal sur-
face up onto Petri dish lids. The mucosa was gently
scraped off with a razor blade and collected in a 1.5 ml
tube. Trizol (1 ml; Invitrogen) was added, the tissue was
homogenized with a disposable pestle (Fisher), and RNA
was isolated per manufacturer protocol (Invitrogen) and
stored at -80°C. Ten (10) ug of RNA were treated with
DNase using a DNA-free kit (Ambion), and 1.6 ug of
treated RNA were reverse transcribed using Superscript III
reverse transcriptase (Invitrogen), per manufacturer pro-
tocol, using random primers in a 20 ul reaction. In paral-BMC Cancer 2009, 9:197 http://www.biomedcentral.com/1471-2407/9/197
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lel control reactions, reverse transcriptase was omitted.
One ul of the reverse transcription reaction was then PCR-
amplified using primers to Engrailed (for detection of the
transgenic transcript) or Actin (control), as previously
described [10], and the products were resolved on a 2%
agarose gel stained with ethidium bromide.
Results
Intestinal En/Erm expression increases tumor number in 
ApcMin mice
We have previously generated and characterized trans-
genic animals expressing the Ets dominant repressor En/
Erm, composed of an HA epitope tag, the Engrailed repres-
sor domain and the DNA-binding domain of the Ets fac-
tor Erm, in the intestinal epithelium under control of the
Villin promoter. En/Erm can potently block transcrip-
tional activation by multiple members of the Ets family
and, when expressed at immunohistochemically detecta-
ble levels in the intestinal epithelium, causes a severe dis-
turbance of crypt-villus homeostasis [10]. We established
additional lines, which stably integrated the Villin-En/
Erm transgene, but did not express En/Erm at immunohis-
tochemically detectable levels. Animals from such lines
did not manifest an overt disturbance of crypt-villus
homeostasis (Figure 1A), indicating a threshold level of
transgene expression for the previously described dra-
matic dysmorphogenesis phenotype [10]. Such animals
did, however, express the transgene at levels detectable by
RT-PCR (Figure 1B). Expression levels of different Ets fac-
tors in the intestine vary widely [9]. We thus wondered
whether such low transgene expressors, free of phenotype
under conditions of normal homeostasis, might manifest
a phenotype under pathologic conditions, by uncovering
a differential requirement for endogenous Ets factor(s)
expressed at lower relative levels.
We thus examined the effect of low-level En/Erm expres-
sion on intestinal epithelial tumorigenesis. Our prior
studies showed that the Villin-En/Erm transgene is
expressed primarily in the small intestine [10]. We there-
fore chose the ApcMin mouse as the tumor model, as these
animals develop multiple epithelial tumors predomi-
nantly in the small intestine [13]. The tumor studies were
carried out in a hybrid (C57BL/6J × FVB/N) genetic back-
ground, since the Villin-En/Erm transgenic lines were gen-
erated in the FVB/N strain while the background of the
ApcMin animals was C57BL/6J. As others have done in sim-
ilar studies [15], we determined the genotype of the major
modifier of tumor multiplicity in the ApcMin  strain,
Mom1, in order to control for possible genetic back-
ground differences between control (ApcMin) and experi-
mental (ApcMin;Villin-En/Erm) groups. Such analyses
indicated that all animals in both control and experimen-
tal groups were heterozygous for the Mom1 locus, and
thus similarly susceptible to ApcMin-driven tumorigenesis.
As shown in Table 1, ApcMin;Villin-En/Erm animals devel-
oped 2.4 times as many total small intestinal tumors as
ApcMin controls (16.5 vs. 6.8, p = 0.03). The ApcMin;Villin-
En/Erm group included approximately equal numbers of
animals from three independent Villin-En/Erm transgenic
lines, each of which developed on average more tumors
than the ApcMin control group (data not shown), indicat-
ing that the differences in tumor number were due to En/
Erm expression rather than transgene integration site
effects. ApcMin;Villin-En/Erm mice developed more
tumors in each intestinal segment (proximal, mid and dis-
tal) compared to the ApcMin controls, although the differ-
ences were greatest and most statistically significant in the
mid small intestine (8.4 vs. 2.8, p = 0.03; Table 1 and Fig-
ure 2). Interestingly, this is the segment where we previ-
ously observed the most severe crypt-villus
dysmorphogenesis phenotypes in high En/Erm expressor
Intestinal histology and En/Erm expression in transgenic ani- mals in the tumor study Figure 1
Intestinal histology and En/Erm expression in trans-
genic animals in the tumor study. (A) Representative 
histology (H+E-stained sections) of mid small intestine from 
non-transgenic (Tg-) and Villin-En/Erm transgenic (Tg+) ani-
mals under conditions of normal homeostasis. The transgenic 
animals show crypt-villus morphology indistinguishable from 
control non-transgenic animals. (B) Levels of Actin and En/
Erm transgene RNA in non-transgenic (Tg-), and transgenic 
(Tg+) animals, as determined by RT-PCR (cycle number: 25).BMC Cancer 2009, 9:197 http://www.biomedcentral.com/1471-2407/9/197
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animals [10]. As expected, tumor numbers in the colon
were lower, and not significantly different between the
ApcMin;Villin-En/Erm and ApcMin groups (0.64 vs. 0.75, p
= 0.80), consistent with the lower levels of transgene
expression in this part of the intestinal tract [10,18]. There
was no significant difference in average overall small
intestinal tumor size between the ApcMin;Villin-En/Erm
and ApcMin groups (Table 1), suggesting that the En/Erm
tumor-promoting effect acts predominantly at an early
stage of tumorigenesis. One exception was the mid small
intestine, where a modest, but statistically significant,
increase in tumor size was observed in the ApcMin;Villin-
En/Erm group (Table 1); hence, locally, En/Erm may also
promote later (post-initiation) stages of tumorigenesis.
Thus, low-level expression of the Ets dominant repressor
En/Erm enhances intestinal tumorigenesis in ApcMin mice.
As discussed, the low expressor transgenic animals in the
tumor studies did not manifest an overt intestinal dys-
morphogenesis phenotype, as judged by H+E histomor-
phology, in contrast to the previously described high
expressor animals [10]. To determine whether more sub-
tle phenotypes might be present under conditions of
homeostasis, we performed additional analyses. As
shown in Fig. 3, Mcm6 immunohistochemical staining
confirmed the presence of normal epithelial maturation
in the Villin-En/Erm animals, indistinguishable from
non-transgenic controls. Interestingly, by in vivo BrdU
labeling, the low expressor En/Erm animals did show a
modest increase in crypt-villus epithelial transit, smaller
than previously described in high expressors [10], but
clearly different from non-transgenic controls (Figure 3).
Thus, the tumor-promoting effect of En/Erm may act in
part by increasing epithelial turnover.
Effect of En/Erm expression on tumor invasiveness in 
ApcMin mice
By histologic analysis, tumors in both control (ApcMin)
and experimental (ApcMin;Villin-En/Erm) groups
included adenomas and adenocarcinomas with similar
morphologic features. We found evidence of stromal inva-
sion (of the lamina propria and beyond; Figure 4A–C) in
70% of the animals. There was a trend toward greater
invasiveness in the ApcMin;Villin-En/Erm group (19.3%
vs. 10.9% of tumors), although this difference did not
reach statistical significance (p = 0.17) (Table 1). Further,
nearly one third of the tumors showing stromal invasion
manifested highly aggressive histology, characterized by
Table 1: Summary of animal tumor data
ApcMin
(n = 12)
ApcMin; Villin-En/Erm
(n = 11)
Mean (SEM) Mean (SEM) p-value**
Animal age (months) 14.3 (1.3) 13.0 (1.1) 0.45
Tumor number (total) 6.8 (2.0) 16.5 (3.4) 0.03
PSI 1.3 (0.1) 3.4 (0.2) 0.07
MSI 2.8 (0.3) 8.4 (0.4) 0.03
DSI 2.9 (0.3) 4.8 (0.4) 0.37
Tumor size (total; cm)* 0.31 (0.03) 0.31 (0.02) 0.89
PSI 0.33 (0.07) 0.25 (0.04) 0.33
MSI 0.20 (0.02) 0.27 (0.01) 0.001
DSI 0.32 (0.04) 0.32 (0.02) 0.82
% tumors with stromal invasion 10.9 (4.6) 19.3 (4.6) 0.17
% histologically aggressive tumors 3.7 (2.8) 4.7 (2.4) 0.78
* largest dimension from slide
** from two-tailed student t-test with unequal variance
SEM: standard error of the mean
PSI, MSI and DSI: proximal, mid and distal small intestine, respectivelyBMC Cancer 2009, 9:197 http://www.biomedcentral.com/1471-2407/9/197
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small, poorly differentiated glands and clusters of malig-
nant epithelial cells in a densely collagenized, desmoplas-
tic stroma (Figure 4D and 4E). Such tumors expressed
high levels of both cytoplasmic and nuclear (activated) b-
catenin, but retained epithelial characteristics, including
membranous E-cadherin expression (Figure 4F and 4G).
Adenomas associated with such tumors tended to contain
regions with cytologic features of high-grade dysplasia,
including large nuclei with prominent nucleoli and brisk
mitotic activity (data not shown). The incidence of these
aggressive tumors was not significantly different between
the experimental (ApcMin;Villin-En/Erm) and control
(ApcMin) groups (4.7% vs. 3.7%, p = 0.78). Thus, a rela-
tively high proportion of ApcMin-induced neoplastic
lesions gives rise to invasive and histologically aggressive
adenocarcinomas in a C57BL/6J × FVB/N hybrid genetic
background, and En/Erm-expressing tumors show a trend
toward greater stromal invasiveness.
Discussion
Members of the Ets transcription factor family are fre-
quently misexpressed or otherwise dysregulated in diverse
human malignancies [1,4,5]. Although Ets factors have
been shown to regulate a variety of cellular processes rele-
vant to tumorigenesis [1,4,5], relatively little is known
about their effects on tumor initiation and/or progression
in vivo. Indeed, to date, few studies have examined Ets
functions in tumorigenesis using animal genetic models
(Table 2). In mouse models of breast cancer, Pea3 and
Ets2 have been shown to exert tumor-promoting effects,
the former in the epithelium and the latter in the stroma
[6-8]. In the present study, we examined the effect of
expression of the Ets dominant repressor transgene En/
Erm on ApcMin-driven tumorigenesis in the intestine.
Suprisingly, we find that low-level expression of En/Erm
in the intestinal epithelium more than doubles the tumor
number in ApcMin mice. This effect appears to act at an
early stage in tumor formation, as En/Erm seems to have
little effect on tumor size. Interestingly, while lacking the
overt crypt-villus dysmorphogenesis phenotype of high-
expressor animals, the low-expressor mice analyzed in
this tumor study do retain a degree of increased crypt-vil-
Tumor number in the small intestines of ApcMin and ApcMin;  Villin-En/Erm mice, broken down by longitudinal segment  (PSI, MSI and DSI denote proximal, mid and distal small intes- tine, respectively) Figure 2
Tumor number in the small intestines of ApcMin and 
ApcMin; Villin-En/Erm mice, broken down by longitu-
dinal segment (PSI, MSI and DSI denote proximal, 
mid and distal small intestine, respectively). Data are 
expressed as mean and standard error of the mean.
Analysis of epithelial maturation and transit in the small intes- tines of En/Erm low-expressor mice (Tg+) and non-transgenic  controls (Tg-) Figure 3
Analysis of epithelial maturation and transit in the 
small intestines of En/Erm low-expressor mice (Tg+) 
and non-transgenic controls (Tg-). Transgenic animals 
show appropriate loss of nuclear Mcm6 expression along the 
crypt-villus axis, indistinguishable from controls, reflecting 
normal epithelial maturation. In contrast, crypt-villus epithe-
lial transit, as determined by in vivo BrdU labeling [10], is 
increased in transgenic animals compared to controls (top 
solid line: villus tips; bottom solid line: crypt-villus junction; 
dashed line: overall upper limit of epithelial transit; arrow-
heads: upper limit of epithelial transit in individual villi). Rep-
resentative images of mid small intestine are shown for both 
groups.BMC Cancer 2009, 9:197 http://www.biomedcentral.com/1471-2407/9/197
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Invasive adenocarcinomas in animals in tumor study Figure 4
Invasive adenocarcinomas in animals in tumor study. (A-C) H+E-stained (A: low-power view; B: high-power view) and 
SMAimmunostained (C) histologic sections of a representative invasive tumor. Note neoplastic epithelium invading through the 
muscularis propria (mp) of the intestinal wall (solid arrowheads) and into the outermost serosa layer (s and open arrowheads; 
m: mucosa; SMA immunostain highlights well-oriented muscularis propria layer). (D-G) Histologically aggressive lesions. H+E-
stained (D: lowpower view; E: high-power view) histologic sections showing poorly formed glands and clusters of neoplastic 
epithelial cells (asterisk in D and arrow in E) in a densely collagenized desmoplastic stroma. These aggressive lesions express 
high-levels of cytoplasmic and nuclear beta-catenin (arrowhead in F; inset: detailed view), but retain membranous E-cadherin 
expression (arrowheads in G; inset: detailed view).BMC Cancer 2009, 9:197 http://www.biomedcentral.com/1471-2407/9/197
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lus epithelial transit. This suggests that the En/Erm tumor-
promoting effect may act in part through increased epithe-
lial turnover. As an interesting corollary, it also implies
that epithelial maturation and transit, found to be coordi-
nately disrupted in the high-expressor En/Erm animals
[10], are regulated by different mechanisms, as the pheno-
types are genetically separable in the low-expressor mice.
Most Ets factors function as transcriptional activators
[1,2]. Since En/Erm exerts its effect by blocking Ets-medi-
ated transcriptional activation [10], our findings imply
that the endogenous Ets factors blocked by En/Erm nor-
mally function to restrict tumorigenesis in the intestinal
epithelium. Due to the high conservation of the Ets
domain, the En/Erm protein is able to block transcrip-
tional activation by multiple different Ets factors [10],
making it difficult to determine which individual Ets is/
are responsible for this tumorigenesis-modifying effect.
We have previously shown that higher (immunohisto-
chemically detectable) levels En/Erm expression result in
small intestinal crypt-villus dysmorphogenesis, probably
by interfering with the activity of relatively abundant Ets
factors in the intestine, such as Elf3, Ehf and/or Ets2 [10].
In contrast, possible candidate Ets factors responsible for
the tumor phenotype include those with normally lower
relative expression levels in the intestine, such as Pea3,
Erm and/or Elf 1 [9]. Alternatively, the tumor phenotype
may be uncovering a differential requirement for a more
highly expressed Ets. Interestingly, similar to our findings,
Sussan et al recently observed an inverse relationship
between Ets2 gene copy number and tumor number in the
ApcMin model, suggesting that Ets2 normally functions to
restrict intestinal tumor formation [19]. Thus, while fre-
quently overexpressed in colon cancer, at least some Ets
factors, including Ets2 and those blocked by the En/Erm
transgene in our studies, appear to normally restrict,
rather than promote, epithelial neoplasia in the intestine.
Indeed, it may be that the same Ets factors manifest differ-
ent functions in neoplasia at different expression levels
due to differential promoter binding and regulation.
Secondly, our studies suggest that the ApcMin mutation
may provide a good model of human intestinal cancer in
the C57BL/6J × FVB/N hybrid genetic background. In this
background, the overall tumor burden is lower and the
proportion of invasive lesions higher than in the pure
C57BL/6J background, in which animals die relatively
early from intestinal obstruction caused by numerous
non-invasive adenomas. Thus, this mixed background
model approximates the human disease, and could be
useful for studying genetic parameters controlling carci-
noma invasion and metastasis.
Conclusion
Expression of the Ets dominant repressor En/Erm in the
small intestine, at levels that do not cause crypt-villus dys-
morphogenesis, results in a marked increase in tumor
number in the ApcMin model of intestinal carcinoma.
Tumor size is relatively unaffected, indicating that this
effect acts predominantly at the level of tumor initiation
or/and early promotion. Histologic examination of the
tumors suggests that En/Erm expression may also pro-
mote stromal invasion. Together, these findings from an
animal genetic model provide in vivo evidence for an
unexpected role for endogenous Ets factors in the restric-
tion of epithelial tumorigenesis in the intestine. Moreo-
ver, our studies suggest that the ApcMin mutation may
provide a good model for invasive human intestinal carci-
noma in the C57BL/6J × FVB/N hybrid genetic back-
ground.
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Table 2: Summary of genetic studies examining Ets factor functions in tumorigenesis
Ets Genetic manipulation Tissue Tumor model Effect on tumorigenesis Subcompartment with 
effect
Reference
PEA3 subfamily Dominant negative Mammary gland MMTV-Neu Inhibition 
(increased latency; decreased 
number and size)
Epithelium [7]
Ets2 Hypomorphic mutant Mammary gland MMTV-PyMT
MMTV-Neu
Inhibition 
(increased latency; decreased 
number and size)
Stroma [6,8]
Ets2 One extra gene copy Intestine ApcMin Inhibition 
(decreased number)
Not determined [18]
Ets family Dominant repressor Intestine ApcMin Promotion
(increased number)
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